| Gene symbol | TNFRSF13C | Synonyms | BAFF-R, BAFFR, BROMIX, CD268, CVID4, prolixin | Type of gene | protein-coding |
| Chromosome | 22 | Map location | 22q13.2 | dbXrefs | |
| Description | TNF receptor superfamily member 13C | ||||
| GTO ID | GTC3702 |
| Trial ID | NCT06191887 |
| Disease | B-Cell Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma |
| Altered gene | BAFFR |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | MC10029 |
| Co-treatment | Bendamustine |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase 1a/1b Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells (MC10029) in Subjects With Relapsed or Refractory BAFFR-Expressing B-Cell Hematologic Malignancies |
| Year | 2024 |
| Country | United States |
| Company sponsor | Mayo Clinic |
| Other ID(s) | MC230807|NCI-2023-10077|23-004166|MC230807 |
| Cohort 1 | |||||||||||
|
|||||||||||